Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06320626` - Pharmacokinetic-guided Dosing of Emicizumab	Phase 4
Completed	`NCT04072237` - Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia	Phase 1
Not yet recruiting	`NCT02554526` - Basic Study of Combination Therapy Based on APCC-induced FVllI Activation in Hemophilia A Patients With Inhibitors	N/A
Completed	`NCT03818529` - ATHN 8: Previously Untreated Patients (PUPs) Matter Study
Active, not recruiting	`NCT03619863` - ATHN 7: Hemophilia Natural History Study
Recruiting	`NCT06010953` - SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment	Phase 1/Phase 2
Completed	`NCT03951103` - rFVIIIFc (Elocta®) ITI Chart Review in Patients With Haemophilia A
Recruiting	`NCT05888870` - ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor	Phase 4
Terminated	`NCT04303572` - The Hemophilia Inhibitor Eradication Trial	Phase 3
Terminated	`NCT04489537` - Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B	Phase 3
Completed	`NCT06357572` - Real-life Clinical FEIBA Samples Measured Using the Version A of the HemA EnzySystem
Recruiting	`NCT04647227` - SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors	Phase 4
Completed	`NCT03372993` - Prospective, Non-interventional Study to Evaluate Immunogenicity of AryoSeven
Terminated	`NCT03204539` - INdividualized ITI Based on Fviii(ATE) Protection by VWF	Phase 4
Active, not recruiting	`NCT04205175` - A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab	Phase 4
Recruiting	`NCT06312475` - Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors	Phase 3
Recruiting	`NCT03598725` - Low-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in China	Phase 4
Completed	`NCT04723693` - An Exploration of the Impact of Emicizumab on the Lives of People With Haemophilia and Inhibitors and Their Families
Completed	`NCT04789954` - Study on the Dose-response Relationship of Pharmacodynamic Parameters in Patients With Hemophilia With Inhibitors	Early Phase 1
Recruiting	`NCT04592692` - A Pharmacokinetic and Clotting Activity Study of FVIII-PEGLip	Phase 2

NCT number	NCT04548791
Study type	Interventional
Source	Catalyst Biosciences
Contact
Status	Terminated
Phase	Phase 1/Phase 2
Start date	May 17, 2021
Completion date	December 3, 2021

Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms